Honokiol

Catalog No.S2310 1 Product Citations

Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Price Stock Quantity  
In DMSO USD 110 In stock
USD 88 In stock
USD 148 In stock
USD 260 In stock
USD 480 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Honokiol Chemical Structure

Honokiol Chemical Structure
Molecular Weight: 266.334

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Honokiol is available in the following compound libraries:

Product Information

  • Compare Akt Inhibitors
    Compare Akt Products
  • Research Area

Product Description

Biological Activity

Description Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.
Targets Akt-phosphorylation [1]
In vitro Honokiol shows pro-apoptotic effects in melanoma, sarcoma, myeloma, leukemia, bladder, lung, prostate, oral squamous cell carcinoma and colon cancer cell lines. Honokiol is effective on inducing apoptosis in SVR angiosarcoma cells. Treatment of SVR cells with honokiol causes decreased phosphorylation of MAP kinase, akt, and c-src. In addition, honokiol potentiates TRAIL-mediated apoptosis, and honokiol cytotoxicity is partially abrogated by neutralizing antibodies to TRAIL. Honokiol also has direct antiangiogenic activity, in that honokiol blocks the phosphorylation and rac activation due to VEGF-VEGFR2 interactions. [1] Honokiol causes apoptosis in CLL cells through activation of caspase 8, followed by caspase 9 and 3 activation. Honokiol prevents interleukin-4-mediated survival of CLL cells, and potentiats the cytotoxicity of chlorambucil, fludarabine, and cladribine. [3] Honokiol kills myeloma cells from relapsed patients at doses that does not kill PBMCs. Caspase 3, 7, 8, and 9 are induced by honokiol treatment, as well as PARP cleavage. [2] Honokiol is found to induce apoptosis in the colon cancer cell lines RKO. [4] Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. [5] Honokiol may act as a potent anti-inflammatory agent with multipotential activities due to an inhibitory effect on the PI3K/Akt pathway. [6]
In vivo Honokiol is highly effective against SVR angiosarcoma in nude mice. [1] Honokiol inhibits the growth of RKO cells in murine xenografts. [4] Honokiol prevents the growth of MDA-MD-231 breast cancer cells in murine xenografts. [7]
Features

Protocol(Only for Reference)

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km
Example

For example, to convert the dose of resveratrol used in a mouse (22.4 mg/kg) to a dose based on surface area for rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Bai X, et al. J Biol Chem, 2003, 278(37), 35501-35507.

[2] Ishitsuka K, et al. Blood, 2005, 106(5), 1794-800.

view more

Chemical Information

Download Honokiol SDF
Molecular Weight (MW) 266.334
Formula

C18H18O2

CAS No. 35354-74-6
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Synonyms
Solubility (25°C) * In vitro DMSO 53 mg/mL (198 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Research Area

Product Citations (1)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Akt Products

  • Dorsomorphin 2HCl

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits BMP type I receptor.

  • VE-822

    VE-822 is an ATR inhibitor with IC50 of 19 nM.

    Features:VE-822 is a highly selective and potent derivative of the ATR inhibitor VE-821.

  • WZ4003

    WZ4003 is a highly specific NUAK kinase inhibitor with IC50 of 20 nM and 100 nM for NUAK1 and NUAK2, respectively, without significant inhibition on 139 other kinases.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • CCT128930

    CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 with IC50 of 6 nM, 28-fold greater selectivity for Akt2 than the closely related PKA kinase.

Recently Viewed Items

Tags: buy Honokiol | Honokiol supplier | purchase Honokiol | Honokiol cost | Honokiol manufacturer | order Honokiol | Honokiol distributor
Contact Us